HUP0203197A2 - Docetaxel alkalmazása hepatocelluláris karcinómák kezelésére - Google Patents

Docetaxel alkalmazása hepatocelluláris karcinómák kezelésére

Info

Publication number
HUP0203197A2
HUP0203197A2 HU0203197A HUP0203197A HUP0203197A2 HU P0203197 A2 HUP0203197 A2 HU P0203197A2 HU 0203197 A HU0203197 A HU 0203197A HU P0203197 A HUP0203197 A HU P0203197A HU P0203197 A2 HUP0203197 A2 HU P0203197A2
Authority
HU
Hungary
Prior art keywords
docetaxel
hepatocellular carcinoma
treating hepatocellular
treatment
treating
Prior art date
Application number
HU0203197A
Other languages
English (en)
Inventor
Gar-Yang Chau
Chin-Wen Chi
Heng-Liang Lin
Tsung-Yun Liu
Wing-Yiu Lui
Original Assignee
Aventis Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma S.A. filed Critical Aventis Pharma S.A.
Publication of HUP0203197A2 publication Critical patent/HUP0203197A2/hu
Publication of HUP0203197A3 publication Critical patent/HUP0203197A3/hu
Publication of HU228861B1 publication Critical patent/HU228861B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A találmány tárgya hatóanyagként docetaxelt tartalmazó készítményhepatocelluláris karcinóma kezelésére. A találmány azon a felismerésenalapul, hogy a docetaxel szignifikánsan aktívabb hepatocelluláriskarcinóma sejtek ellen, mint a paclitaxel 1 mM koncentrációkig. Ennekértelmében ez lehetőséget biztosít a docetaxel felhasználására egyolyan gyógyszer előállításában, amely hepatocelluláris karcinómakezelésében alkalmazható. Ó
HU0203197A 1999-08-31 2000-08-29 Docetaxel alkalmazása hepatocelluláris karcinómák kezelésére alkalmas gyógyszer elõállítására HU228861B1 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9920548.6A GB9920548D0 (en) 1999-08-31 1999-08-31 Treatment of hepatocellular carcinoma
PCT/EP2000/008782 WO2001015675A2 (en) 1999-08-31 2000-08-29 Use of docetaxel for treating hepatocellular carcinoma

Publications (3)

Publication Number Publication Date
HUP0203197A2 true HUP0203197A2 (hu) 2003-01-28
HUP0203197A3 HUP0203197A3 (en) 2005-01-28
HU228861B1 HU228861B1 (hu) 2013-06-28

Family

ID=10860081

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0203197A HU228861B1 (hu) 1999-08-31 2000-08-29 Docetaxel alkalmazása hepatocelluláris karcinómák kezelésére alkalmas gyógyszer elõállítására

Country Status (34)

Country Link
US (2) US20030158249A1 (hu)
EP (1) EP1214061B1 (hu)
JP (1) JP4866522B2 (hu)
KR (1) KR100670416B1 (hu)
CN (1) CN1174748C (hu)
AT (1) ATE269700T1 (hu)
AU (1) AU777583B2 (hu)
BG (1) BG65913B1 (hu)
BR (1) BR0013625A (hu)
CA (1) CA2382294C (hu)
CZ (1) CZ301378B6 (hu)
DE (1) DE60011794T2 (hu)
DK (1) DK1214061T3 (hu)
EA (1) EA004804B1 (hu)
EE (1) EE05124B1 (hu)
ES (1) ES2218223T3 (hu)
GB (1) GB9920548D0 (hu)
HK (1) HK1048944B (hu)
HR (1) HRP20020171A2 (hu)
HU (1) HU228861B1 (hu)
IL (2) IL147489A0 (hu)
ME (1) MEP7809A (hu)
MX (1) MXPA02002041A (hu)
NO (1) NO328527B1 (hu)
NZ (1) NZ517604A (hu)
PL (1) PL212612B1 (hu)
PT (1) PT1214061E (hu)
RS (1) RS50148B (hu)
SI (1) SI1214061T1 (hu)
SK (1) SK286378B6 (hu)
TW (1) TW589180B (hu)
UA (1) UA72927C2 (hu)
WO (1) WO2001015675A2 (hu)
ZA (1) ZA200201408B (hu)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1268619C (zh) 2003-05-08 2006-08-09 上海迪赛诺化学制药有限公司 多烯紫杉醇三水化合物的制备方法
US7838551B2 (en) * 2003-12-12 2010-11-23 Quiral Quimica do Basil S.A. Process for the preparation of concentrated, sterile injectable solutions containing docetaxel
US7449196B2 (en) * 2004-07-09 2008-11-11 Robert Sabin Anti tumor compositions and methods of use
KR101643416B1 (ko) 2005-08-31 2016-07-27 아브락시스 바이오사이언스, 엘엘씨 증가된 안정성을 가진 수 난용성 약물의 조성물 및 제조방법
CA2620585C (en) * 2005-08-31 2015-04-28 Abraxis Bioscience, Llc Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
US9839667B2 (en) 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
US20080081051A1 (en) * 2006-09-28 2008-04-03 Robert Sabin Method of manufacturing anti-tumor and anti-viral compositions
JP2010524919A (ja) * 2007-04-23 2010-07-22 サン、ファーマスーティカル、インダストリーズ、リミテッド 医薬組成物
FR2917088B1 (fr) * 2007-06-08 2009-09-04 Aventis Pharma Sa Dissolution directe du docetaxel dans un solvant dans le polysorbate 80
US8541360B2 (en) * 2008-11-19 2013-09-24 Ben Venue Laboratories, Inc. Parenteral formulations comprising sugar-based esters and ethers
MX346861B (es) 2010-03-26 2017-04-04 Abraxis Bioscience Llc * Metodos de tratamiento de carcinoma hepato celular.
CN109745287A (zh) * 2010-05-03 2019-05-14 帝国制药美国公司 非水性紫杉烷前-乳剂制剂以及制备和使用该制剂的方法
US8842114B1 (en) 2011-04-29 2014-09-23 Nvidia Corporation System, method, and computer program product for adjusting a depth of displayed objects within a region of a display
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
US20160250177A1 (en) * 2015-02-17 2016-09-01 Mallinckrodt Llc Modified docetaxel liposome formulations and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2629819B1 (fr) * 1988-04-06 1990-11-16 Rhone Poulenc Sante Procede de preparation de derives de la baccatine iii et de la desacetyl-10 baccatine iii
US5543154A (en) * 1991-12-27 1996-08-06 Merck & Co., Inc. Controlled release nifedipine delivery device
DK0680320T3 (da) * 1993-01-19 1999-10-25 Warner Lambert Co Stabilt oralt CI-981-præparat og fremgangsmåde til fremstilling deraf
US5846945A (en) * 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5436243A (en) * 1993-11-17 1995-07-25 Research Triangle Institute Duke University Aminoanthraquinone derivatives to combat multidrug resistance
FR2718963B1 (fr) * 1994-04-25 1996-05-24 Rhone Poulenc Rorer Sa Nouvelle composition pharmaceutique à base de taxoïdes.
FR2722191B1 (fr) * 1994-07-08 1996-08-23 Rhone Poulenc Rorer Sa Procede de preparation du trihydrate du (2r,3s)-3-tertbutoxycarbonylamino-2-hydroxy-3-phenylpropionate de 4-acetoxy2alpha-benzoyloxy-5beta,20epoxy-1,7beta,10beta trihydroxy-9-oxo-tax-11-en-13alpha-yle
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US5968972A (en) 1995-10-26 1999-10-19 Baker Norton Pharmaceuticals, Inc. Method for increasing the oral bioactivity of pharmaceutical agents
FR2742751B1 (fr) * 1995-12-22 1998-01-30 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
AU741439B2 (en) * 1996-12-30 2001-11-29 Battelle Memorial Institute Formulation and method for treating neoplasms by inhalation
US6503893B2 (en) * 1996-12-30 2003-01-07 Bone Care International, Inc. Method of treating hyperproliferative diseases using active vitamin D analogues
IL133672A0 (en) * 1997-06-27 2001-04-30 Vivorx Pharmaceuticals Inc Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
AU1146099A (en) * 1997-09-18 1999-04-05 Janssen Pharmaceutica N.V. Fused imidazole derivatives for improving oral bioavailability of pharmaceuticalagents
AU1289899A (en) * 1997-10-31 1999-05-24 Arch Development Corporation Methods and compositions for regulation of 5-alpha reductase activity
UA73092C2 (uk) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
CN1346282A (zh) * 1998-12-23 2002-04-24 G.D.西尔公司 在肿瘤的治疗中使用环加氧酶－2－抑制剂与一种或多种抗肿瘤剂作为联合治疗的方法
GB9909925D0 (en) * 1999-04-29 1999-06-30 Pharmacia & Upjohn Spa Combined preparations comprising anthracycline derivatives
KR20100023059A (ko) * 2005-12-13 2010-03-03 테바 파마슈티컬 인더스트리즈 리미티드 아토바스타틴 헤미칼슘의 결정형 및 이의 제조 방법

Also Published As

Publication number Publication date
NO328527B1 (no) 2010-03-08
NZ517604A (en) 2004-04-30
EP1214061A2 (en) 2002-06-19
DE60011794T2 (de) 2005-07-14
CN1372466A (zh) 2002-10-02
CN1174748C (zh) 2004-11-10
HK1048944B (zh) 2005-04-22
IL147489A0 (en) 2002-08-14
MXPA02002041A (es) 2002-08-20
PL353198A1 (en) 2003-11-03
HK1048944A1 (en) 2003-04-25
UA72927C2 (uk) 2005-05-16
IL147489A (en) 2006-06-11
PT1214061E (pt) 2004-09-30
US20030158249A1 (en) 2003-08-21
US20080045584A1 (en) 2008-02-21
ME00624B (me) 2011-12-20
BG65913B1 (bg) 2010-05-31
MEP7809A (en) 2011-12-20
SI1214061T1 (en) 2004-12-31
JP2003508427A (ja) 2003-03-04
WO2001015675A3 (en) 2001-09-20
CA2382294A1 (en) 2001-03-08
DK1214061T3 (da) 2004-11-01
PL212612B1 (pl) 2012-10-31
RS50148B (sr) 2009-05-06
HRP20020171A2 (en) 2004-02-29
HU228861B1 (hu) 2013-06-28
EE200200087A (et) 2003-04-15
HUP0203197A3 (en) 2005-01-28
JP4866522B2 (ja) 2012-02-01
CZ301378B6 (cs) 2010-02-03
YU11402A (sh) 2005-07-19
WO2001015675A2 (en) 2001-03-08
GB9920548D0 (en) 1999-11-03
CA2382294C (en) 2008-06-03
NO20020829L (no) 2002-02-20
BR0013625A (pt) 2002-05-14
TW589180B (en) 2004-06-01
DE60011794D1 (de) 2004-07-29
ZA200201408B (en) 2003-07-30
SK2712002A3 (en) 2002-07-02
EA200200313A1 (ru) 2002-08-29
BG106460A (bg) 2002-09-30
NO20020829D0 (no) 2002-02-20
EE05124B1 (et) 2009-02-16
EP1214061B1 (en) 2004-06-23
CZ2002739A3 (cs) 2002-06-12
EA004804B1 (ru) 2004-08-26
SK286378B6 (sk) 2008-08-05
AU777583B2 (en) 2004-10-21
KR20020060166A (ko) 2002-07-16
ATE269700T1 (de) 2004-07-15
AU7516800A (en) 2001-03-26
ES2218223T3 (es) 2004-11-16
KR100670416B1 (ko) 2007-01-17

Similar Documents

Publication Publication Date Title
HUP0203197A2 (hu) Docetaxel alkalmazása hepatocelluláris karcinómák kezelésére
HUP0104709A2 (hu) Eritropoietin vagy eritropoietrinszármazékok alkalmazása agyi iszkémiák kezelésére használható gyógyszer előállítására
HUP0102521A2 (hu) Sztilbénszármazékot és platina koordinációs vegyületet tartalmazó daganatellenes szer
DE60236541D1 (de) Inhibitoren von 11-beta-hydroxysteroiddehydrogenase typ 1
SE0001899D0 (sv) New compounds
HUP0203623A2 (hu) Tramadol-szacharinátot tartalmazó, késleltetett hatású adagolási forma és alkalmazása
HUP0400689A2 (hu) ABCA-1 szint-emelő vegyületek
ATE504294T1 (de) Nichtnukleosidische reverse-transkriptase-hemmer
NO20052494D0 (no) Preparater inneholdende melatonin, gingko biloba og biotin.
MY147643A (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
HUP0303838A2 (hu) Eritropoietin mérsékli a kemoterápia-indukált toxicitást in vivo
MXPA04001256A (es) Productos de combinacion de derivados de propanolamina aril substituidos con otros ingredientes activos y su uso.
TR200302134T4 (tr) 2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı.
SE0001916D0 (sv) Novel formulation
NO20032597D0 (no) Anvendelse av SARP-1 for behandlingen og/eller forebyggingen av skleroderma
DK1273301T3 (da) Farmaceutiske præparater baseret på aktive bestanddele der kan anvendes til ulovlig administration
SE0203817D0 (sv) New composition
HUP0300717A2 (hu) Mirtazapint és paracetamolt vagy nem szteroid gyulladáscsökkentő gyógyszert tartalmazó gyógyszerkombináció fejfájás kezelésére
ATE293983T1 (de) Verwendung von n-acetyl-d-glucosamin bei der herstellung eines arzneimittels zur unterdrückung der nebenwirkungen von strahlentherapie und chemotherapie
MXPA04006269A (es) Composicion farmaceutica que comprende un inhibidor de alfa-glucosidasa y acido 4-oxobutanoico y uso de la misma para tratamiento de diabetes.
HUP0402645A2 (hu) Egy glitazont és egy 4-oxobutánsavat tartalmazó gyógyászati készítmény és ennek alkalmazása cukorbetegség kezelésére
DE50304524D1 (de) Arzneimittel enthaltend substituierte 2,5-diaminomethyl-1h-pyrrole
ATE382363T1 (de) Pharmazeutische zusammensetzung enthaltend bulbophyllum

Legal Events

Date Code Title Description
FH91 Appointment of a representative

Free format text: FORMER REPRESENTATIVE(S): BELICZAY LASZLO, S.B.G. & K. SZABADALMI UEGYVIVOEI IRODA, HU

Representative=s name: DANUBIA SZABADALMI ES JOGI IRODA KFT., HU

FH92 Termination of representative

Representative=s name: BELICZAY LASZLO, S.B.G. & K. SZABADALMI UEGYVI, HU

MM4A Lapse of definitive patent protection due to non-payment of fees